Characterization of susceptibility profiles for the CCR5 antagonist vicriviroc in treatment-naive HIV-infected subjects

被引：0
|
作者：
Landovitz, R.
Faetkenhauer, G.
Hoffmann, C.
Horst, H.
Strizki, J.
Whitcomb, J.
Gheyas, F.
Knepp, D.
Greaves, W.
机构：
[1] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA
[2] Univ Cologne, Dept Internal Med, D-5000 Cologne 41, Germany
[3] Hosp St George, Dept Internal Med, Hamburg, Germany
[4] Univ Kiel, Dept Internal Med, D-24098 Kiel, Germany
[5] Monogram Biosci Inc, San Francisco, CA USA
来源：
ANTIVIRAL THERAPY | 2006年 / 11卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：S23 / S23
页数：1
相关论文
共 50 条
  • [31] Influenza virus vaccine decreases CCR5 expression in HIV-infected children
    Reactions Weekly, 2004, 1024 (1) : 5 - 5
  • [32] Overcoming IKR issues in the search for a CCR5 antagonist for the treatment of HIV
    Price, DA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U155 - U155
  • [33] Maraviroc - a CCR5 antagonist for the treatment of HIV-1 infection
    Van Der Ryst, Elna
    FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [34] In vivo emergence of HIV-1 resistance to the CCR5 antagonist vicriviroc:: findings from ACTG A5211
    Tsibris, A. M. N.
    Gulick, R. M.
    Su, Z.
    Hughes, M. D.
    Flexner, C.
    Wilkin, T.
    Gross, R.
    Hirsch, M.
    Skolnick, P. R.
    Coakley, E.
    Greaves, W. L.
    Kuritzkes, D. R.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S15 - S15
  • [35] Virological Response after Short-Term CCR5 Antagonist Exposure in HIV-Infected Patients: Frequency of Subjects with Virological Response and Associated Factors
    Ruiz-Mateos, Ezequiel
    Gonzalez-Serna, Alejandro
    Genebat, Miguel
    Machmach, Kawthar
    Vidal, Francesc
    Munoz-Fernandez, Angeles
    Ferrando-Martinez, Sara
    Leal, Manuel
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (10) : 4664 - 4669
  • [36] In vivo emergence of HIV-1 resistance to the CCR5 antagonist vicriviroc:: findings from ACTG A5211
    Tsibris, A. M. N.
    Gulick, R. M.
    Su, Z.
    Hughes, M. D.
    Flexner, C.
    Wilkin, T.
    Gross, R.
    Hirsch, M.
    Skolnick, P. R.
    Coakley, E.
    Greaves, W. L.
    Kuritzkes, D. R.
    ANTIVIRAL THERAPY, 2007, 12 : S15 - S15
  • [37] The effects of RANTES/CCR5 promoter polymorphisms on HIV disease progression in HIV-infected Koreans
    Jang, D. H.
    Choi, B. -S.
    Kim, S. S.
    INTERNATIONAL JOURNAL OF IMMUNOGENETICS, 2008, 35 (02) : 101 - 105
  • [38] Genetic characterization and antiretroviral resistance mutations among treatment-naive HIV-infected individuals in Jiaxing, China
    Guo, Jinlei
    Yan, Yong
    Zhang, Jiafeng
    Ji, Jimei
    Ge, Zhijian
    Ge, Rui
    Zhang, Xiaofei
    Wang, Henghui
    Chen, Zhongwen
    Luo, Jianyong
    ONCOTARGET, 2017, 8 (11) : 18271 - 18279
  • [39] Prevalence of transmitted drug resistance in hiv-infected treatment-naive patients in Chile
    Palma P, Valeria
    Leiva B, Intty
    Duran P, Magdalena
    Ramos V, Veronica
    Sanchez, Constanza
    Beltran B, Carlos
    Afani S, Alejandro
    Ferrer C, Pablo
    REVISTA MEDICA DE CHILE, 2020, 148 (11) : 1550 - 1557
  • [40] Boosted darunavir as a new therapeutic option for treatment-naive HIV-infected patients
    Dabrowska, Magdalena Monika
    Wiercinska-Drapalo, Alicja
    HIV & AIDS REVIEW, 2009, 8 (03): : 5 - 7
12345